On this page
⚠ Educational content only Not medical or genetic advice. Speak with a healthcare provider or genetic counsellor before acting on anything here.

EIF2B5

eukaryotic translation initiation factor 2B subunit epsilon

The EIF2B5 gene provides instructions for a subunit of the eIF2B protein, which plays a crucial role in regulating protein production within cells. EIF2B5 is essential for cellular function, as its encoded protein helps manage how and when proteins are made.

Chromosome 3q27.1 Various HGNC:3261 Tier C
EIF2B5 3q27.1 p arm q arm 3

EIF2B5 is located on the long (q) arm of chromosome 3, at band 3q27.1. Arm ratio per GRCh38 - banding schematic.

Explore chromosome 3 in the library →

Available at Jeen Health

Clinical tests that include this

Overview

The EIF2B5 gene, also known as eukaryotic translation initiation factor 2B subunit epsilon, encodes one of five subunits of the eIF2B protein. This protein complex is vital for controlling the rate of protein synthesis, a fundamental cellular process. Proper regulation of protein production is critical for cells to adapt to various conditions, such as growth or stress.

Changes in the EIF2B5 gene can affect the eIF2B protein's function, leading to conditions that impact neurological development and function.

What the gene does

The EIF2B5 gene provides the blueprint for the epsilon subunit of the eukaryotic translation initiation factor 2B (eIF2B) protein. The eIF2B protein is a guanine nucleotide exchange factor, meaning it facilitates the exchange of GDP for GTP on another protein called eIF2. This exchange is a key step in initiating protein synthesis, ensuring that the cellular machinery is ready to start building new proteins.

Under certain cellular conditions, eIF2B promotes protein synthesis by helping to recycle GTP molecules, which provide energy for the initiation process. In other scenarios, eIF2B can slow down protein production by binding tightly to eIF2, making it inactive and preventing GTP recycling. This precise regulation ensures cells can adjust protein levels to cope with changing demands, such as during cell division or periods of rest.

Video: Genetics 101

Chromosome location

The EIF2B5 gene is located on chromosome 3 at position q27.1. This specific location on the long arm (q) of chromosome 3 helps pinpoint its genomic address within the human genome.

Protein structure

The EIF2B5 gene encodes a protein consisting of 721 amino acids. The protein structure includes several notable regions. There are three disordered regions: one spanning amino acids 1-40, another from amino acids 444-483, and a third from amino acids 523-547. Additionally, a distinct W2 domain is present, encompassing amino acids 543-720, which is likely important for the protein's function.

Domain map · 721 amino acids
W2 (543–720)W2543–7201~361721
Domain - independent functional unit
🧬 Explore 3D structure on AlphaFold
UniProt:Q13144Length:721 aaStructure:AlphaFold

Key variants

Genetic variations within the EIF2B5 gene can range from single nucleotide changes to larger deletions or insertions. These variants may alter the structure or function of the resulting eIF2B5 protein subunit, affecting its role in regulating protein synthesis. Different types of variants can have varying impacts on protein activity and cellular processes.

The table below shows the top 10 pathogenic or likely-pathogenic variants currently classified in ClinVar for EIF2B5.
View all on ClinVar →

Sample of pathogenic variants

10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.

Variant (HGVS) Protein change Classification Evidence Associated condition
c.1289T>C
single nucleotide variant
p.Val430Ala Pathogenic/Likely pathogenic ★★☆☆ Vanishing white matter disease
c.1694delinsTTTCTTGTGCATCTCCACTACAGAGGAGCGGGGCATCTCCACTAC
Indel
p.Lys565fs Pathogenic ★★☆☆ Vanishing white matter disease
c.1813del
Deletion
p.Leu605fs Pathogenic ★★☆☆ Vanishing white matter disease
c.1960del
Deletion
p.Phe653_Leu654insTer Pathogenic/Likely pathogenic ★★☆☆ Leukoencephalopathy with vanishing white matter 5
c.203T>C
single nucleotide variant
p.Leu68Ser Pathogenic/Likely pathogenic ★★☆☆ EIF2B5-related disorder
c.406C>T
single nucleotide variant
p.Arg136Cys Pathogenic/Likely pathogenic ★★☆☆ Leukoencephalopathy with vanishing white matter 5
c.439_442del
Deletion
p.Asp147fs Pathogenic/Likely pathogenic ★★☆☆ Vanishing white matter disease
c.721C>T
single nucleotide variant
p.Arg241Ter Pathogenic/Likely pathogenic ★★☆☆ Vanishing white matter disease
c.799C>T
single nucleotide variant
p.Gln267Ter Pathogenic ★★☆☆ Vanishing white matter disease
c.805C>T
single nucleotide variant
p.Arg269Ter Pathogenic ★★☆☆ Vanishing white matter disease

Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.

Associated conditions

Variants in the EIF2B5 gene are primarily associated with leukoencephalopathy with vanishing white matter. This condition is characterised by the progressive loss of white matter in the brain, which can lead to a range of neurological symptoms. EIF2B5 variants are found in a significant proportion of individuals with this disorder, including specific forms observed in certain populations.

No disease links recorded for this gene in our reference set.

UK clinical status

The EIF2B5 gene is recognised within several UK NHS Genomic Medicine Service national test directories, as indicated by its 'green' status on PanelApp. It is included in panels related to ataxia and cerebellar anomalies (childhood onset), early onset or syndromic epilepsy, hereditary ataxia (both general and adult onset), inherited white matter disorders, leukodystrophy (adult onset), neurodegenerative disorders (adult onset), and primary ovarian insufficiency. It is also listed within the DDG2P (Deciphering Developmental Disorders) panel.

Frequently asked questions

What is the primary function of the EIF2B5 gene?

The EIF2B5 gene provides instructions for the epsilon subunit of the eIF2B protein, which is essential for regulating the initiation of protein synthesis within cells. It helps control the rate at which new proteins are produced, allowing cells to adapt to different conditions.

What condition is most commonly associated with EIF2B5 gene variants?

Variants in the EIF2B5 gene are most commonly associated with leukoencephalopathy with vanishing white matter. This is a neurological disorder characterised by the progressive degeneration of the brain's white matter.

How does the eIF2B protein regulate protein synthesis?

The eIF2B protein regulates protein synthesis by facilitating the exchange of GDP for GTP on the eIF2 protein, a crucial step in initiating protein production. It can either promote synthesis by recycling energy-carrying molecules or slow it down by binding to eIF2, thus controlling cellular protein levels.

References

  1. Fogli A, Boespflug-Tanguy O. The large spectrum of eIF2B-related diseases. Biochemical Society transactions. 2006. PMID: 16246171
  2. Scheper GC, Proud CG, van der Knaap MS. Defective translation initiation causes vanishing of cerebral white matter. Trends in molecular medicine. 2006. PMID: 16545608
  3. Pronk JC, van Kollenburg B, Scheper GC. Vanishing white matter disease: a review with focus on its genetics. Mental retardation and developmental disabilities research reviews. 2006. PMID: 16807905
  4. van Kollenburg B, van Dijk J, Garbern J. Glia-specific activation of all pathways of the unfolded protein response in vanishing white matter disease. Journal of neuropathology and experimental neurology. 2006. PMID: 16825957
  5. Scali O, Di Perri C, Federico A. The spectrum of mutations for the diagnosis of vanishing white matter disease. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2006. PMID: 16998732
  6. Dietrich J, Lacagnina M, Gass D. EIF2B5 mutations compromise GFAP+ astrocyte generation in vanishing white matter leukodystrophy. Nature medicine. 2005. PMID: 15723074
  7. van der Voorn JP, van Kollenburg B, Bertrand G. The unfolded protein response in vanishing white matter disease. Journal of neuropathology and experimental neurology. 2005. PMID: 16141786
  8. Pavitt GD. eIF2B, a mediator of general and gene-specific translational control. Biochemical Society transactions. 2005. PMID: 16246152
  9. Fogli A, Schiffmann R, Hugendubler L. Decreased guanine nucleotide exchange factor activity in eIF2B-mutated patients. European journal of human genetics : EJHG. 2004. PMID: 15054402
  10. Li W, Wang X, Van Der Knaap MS. Mutations linked to leukoencephalopathy with vanishing white matter impair the function of the eukaryotic initiation factor 2B complex in diverse ways. Molecular and cellular biology. 2004. PMID: 15060152
Educational content. This page is not medical or genetic advice, is not individually reviewed by a clinician for each reader, and should not replace a consultation with a qualified healthcare professional or genetic counsellor. If you are considering genetic testing or acting on a test result, book a consultation.
Data sources Last updated 13 September 2026. Content compiled from HGNC · MedlinePlus Genetics · ClinGen · Genomics England PanelApp · NHS National Genomic Test Directory · ClinVar · UniProt · AlphaFold .